文献速递病毒性肝炎

PI4KIII抑制剂enviroxime通过抑制PI3K阻碍丙型肝炎病毒复制

PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该研究利用HCV亚基因组复制子和感染性HCV模型,评估PI4KIII抑制剂enviroxime与BF738735的抗HCV活性及机制。耐药复制子交叉耐药并携带NS3、NS4B、NS5A突变;PI4KIIIβ敲低不影响复制,化合物也不改变PI4P水平或NS5A磷酸化。结论提示两药抗HCV作用并非主要靶向PI4KIIIα/β,而至少部分通过抑制PI3K实现,HCV可经基因组突变绕过PI3K抑制。

要点

  • enviroxime与BF738735抗HCV并非主要经PI4KIIIα/β发挥作用。
  • 两药至少部分通过抑制PI3K阻碍HCV复制。
  • HCV可经NS3、NS4B、NS5A突变对PI3K抑制产生逃逸。

核心结论

  • enviroxime和BF738735抗HCV活性并非主要靶向PI4KIIIα和PI4KIIIβ,而至少部分通过抑制PI3K实现。
  • HCV可通过基因组突变获得对PI3K抑制的逃逸能力。

研究设计与样本

  • 采用HCV亚基因组复制子和感染性HCV进行抗病毒试验。
  • 通过长期培养并逐步提高化合物浓度,筛选enviroxime和BF738735耐药HCV复制子。
  • 用共聚焦显微镜分析细胞内PI4P脂质定位,并用siRNA敲低PI4KIIIβ。

主要发现

  • 对enviroxime或BF738735耐药的HCV亚基因组复制子呈交叉耐药,并携带NS3、NS4B和NS5A基因突变。
  • 本研究中siRNA敲低PI4KIIIβ不影响HCV亚基因组复制子复制。
  • 化合物不影响复制复合物处PI4P脂质水平,也不影响NS5A磷酸化状态。
  • 广谱PI3K抑制剂LY294002对耐药复制子的效力降低10倍。
  • enviroxime和BF738735在酶学试验中抑制多种PI3K。

临床怎么用

  • 提示enviroxime与BF738735的抗HCV机制需重新审视,PI4KIIIα/β并非其主要靶点。
  • 联合或序贯使用PI3K相关通路抑制剂时需警惕HCV经NS3、NS4B、NS5A突变逃逸。

局限性

  • 研究主要基于HCV亚基因组复制子和体外感染模型,结论外推至临床需谨慎。
  • 原文未报告具体样本量、突变位点明细及酶学抑制的剂量效应参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Many positive-stranded RNA viruses, including HCV, drastically remodel intracellular membranes to generate specialized environments for RNA replication. Phosphatidylinositol 4-kinase III (PI4KIII)α plays an essential role in the formation of HCV replication complexes and has therefore been explored as a potential drug target. Here, we characterized the anti-HCV activity of the PI4KIII inhibitors enviroxime and BF738735 and elucidated their mechanism of action. METHODS: Antiviral assays were performed using HCV subgenomic replicons and infectious HCV. Enviroxime- and BF738735-resistant HCV replicons were generated by long-term culture with increasing compound concentrations. Intracellular localization of phosphatidylinositol 4-phosphate (PI4P) lipids was analysed by confocal microscopy. RESULTS: HCV subgenomic replicons resistant to either enviroxime or BF738735 proved cross-resistant and carried mutations in the NS3, NS4B and NS5A genes. Knockdown of PI4KIIIβ by small interfering RNA (siRNA) did not affect the replication of the HCV subgenomic replicon in this study. Furthermore, the compounds did not affect PI4P lipid levels at the replication complexes nor the phosphorylation status of NS5A, activities attributed to PI4KIIIα. Interestingly, the broad-spectrum phosphoinositide 3-kinase (PI3K) inhibitor LY294002 proved to be 10-fold less effective against the resistant replicons. In addition, enviroxime and BF738735 inhibited several PI3Ks in enzymatic assays. CONCLUSIONS: Contrary to assumptions, our data indicate that PI4KIIIα and PI4KIIIβ are not the main targets for the anti-HCV activity of enviroxime and BF738735. Instead, we demonstrated that both molecules impede HCV replication at least partially by an inhibitory effect on PI3Ks. Moreover, HCV is able to bypass PI3K inhibition by acquiring mutations in its genome.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Delang L, Harak C, Benkheil M, et al. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases. J Antimicrob Chemother. 2018. PMID: 30219827. doi:10.1093/jac/dky327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。